Efficacy
non-small lung cancer, PNET, pancreatic Neuroendocrine Tumor, duodenal carcinoma, thymic squamous cell carcinoma, soft-tissue sarcomas, SCLC, death, cancer, SD, gastric cancer, NSCLC, ovarian cancer, small lung cancer, pancreatic cancer, biliary tract cancer, duodenal adenocarcinoma, PD, tumors
PNET, UROTHELIAL CARCINOMA, EVENTS, DUODENAL CARCINOMA, PANCREATIC NEUROENDOCRINE TUMOR, PANCREATIC DUCTAL ADENOCARCINOMA, COLORECTAL CANCER, SCLC, CANCER, ANAPLASTIC THYROID CARCINOMA, UNDIFFERENTIATED SARCOMA, METASTATIC SQUAMOUS CELL CARCINOMA, GASTRIC CANCER, NON-SMALL CELL LUNG CANCER, OVARIAN CANCER, NASOPHARYNGEAL CARCINOMA, GALLBLADDER CARCINOMA, PANCREATIC CANCER, ANAPLASTIC THYROID CANCER, BILIARY TRACT CANCER, DISEASE, CARCINOMA, NSCLC, TUMORS, CHOLANGIOCARCINOMA, STS
At the time of data cutoff (June, 2022), the median duration of follow-up was 9.0 months (95% CI 5.5-12.5). A total of 52 patients were evaluable by RECIST 1.1 criteria, while other 8 patients were not evaluable owing to death or falling off. In terms of overall efficacy, 18 patients had partial response (PR), 24 had stable disease (SD) and 9 had progressive disease (PD). The overall ORR and DCR were 34.6% and 82.7%, respectively (We particularly analyzed the efficacy of patients with target lesions. Of 52 evaluable patients, 50 patients with target lesions were evaluable by RECIST 1.1 criteria, while target lesions of two were unevaluable. The ORR and DCR of patients with target lesions were 36.0% and 96.0%, respectively, as PR was observed in 18 patients, SD in 30 patients, and PD in 2 patients (In the current study, more than 20 types of cancer were included. Nearly half of the subjects were with digestive system tumors including 10 with biliary tract cancer (2 PR, 8 SD), 8 with pancreatic cancer (4 evaluable, 4 SD), 3 with gastric cancer (GC) (2 evaluable, 2 PR), and 2 with duodenal carcinoma (2 PR). Additionally, ten patients with soft-tissue sarcomas (STS) were enrolled, six of which were undifferentiated sarcomas. The ORR was 30.0% (3/10) in STS. Besides some common cancer types, such as ovarian cancer (2 PR, 1 SD) and non-small cell lung cancer (3 evaluable, 1 PR, 1 SD, 1 PD), a few of rare types of cancer were also under investigation in our study. For instance, one patient was with anaplastic thyroid cancer (ATC) (PR), and two were with thymic squamous cell carcinoma (2 PR). The best response of target lesions of each cancer type is shown in Overall efficiency and the target lesions evaluation.Swimmer plot according to cancer type. PR, partial response; SD, stable disease; PD, progressive disease; CCA, cholangiocarcinoma; GBC, gallbladder carcinoma; STS, soft-tissue sarcomas; SCLC, small lung cancer; NSCLC, non-small lung cancer; PDAC, pancreatic ductal adenocarcinoma; CSC, cutaneous squamous cell carcinoma; tSCC, thymic squamous cell carcinoma; cSCC, cutaneous squamous cell carcinoma; mSCC, metastatic squamous cell carcinoma of unknown primary;DPC, duodenal papilla carcinoma; DAC, duodenal adenocarcinoma; CRC, colorectal cancer; UC, Urothelial carcinoma; ATC, Anaplastic thyroid carcinoma; NPC, nasopharyngeal carcinoma; PNET, pancreatic Neuroendocrine Tumor.As shown in Waterfall plot and survival data. At the time of data cutoff, eight patients (13.3%) were still receiving treatment, 40 (66.7%) patients had PFS events, and the mPFS was 5.3 months (95% CI 3.6, 6.2) (